363 related articles for article (PubMed ID: 24759590)
1. Androgen synthesis inhibitors in the treatment of castration-resistant prostate cancer.
Stein MN; Patel N; Bershadskiy A; Sokoloff A; Singer EA
Asian J Androl; 2014; 16(3):387-400. PubMed ID: 24759590
[TBL] [Abstract][Full Text] [Related]
2. The hunt for a selective 17,20 lyase inhibitor; learning lessons from nature.
Bird IM; Abbott DH
J Steroid Biochem Mol Biol; 2016 Oct; 163():136-46. PubMed ID: 27154414
[TBL] [Abstract][Full Text] [Related]
3. Targeting the adrenal gland in castration-resistant prostate cancer: a case for orteronel, a selective CYP-17 17,20-lyase inhibitor.
Zhu H; Garcia JA
Curr Oncol Rep; 2013 Apr; 15(2):105-12. PubMed ID: 23371447
[TBL] [Abstract][Full Text] [Related]
4. Abiraterone acetate: oral androgen biosynthesis inhibitor for treatment of castration-resistant prostate cancer.
Rehman Y; Rosenberg JE
Drug Des Devel Ther; 2012; 6():13-8. PubMed ID: 22291466
[TBL] [Abstract][Full Text] [Related]
5. CYP17 inhibitors--abiraterone, C17,20-lyase inhibitors and multi-targeting agents.
Yin L; Hu Q
Nat Rev Urol; 2014 Jan; 11(1):32-42. PubMed ID: 24276076
[TBL] [Abstract][Full Text] [Related]
6. Agents that target androgen synthesis in castration-resistant prostate cancer.
Ferraldeschi R; de Bono J
Cancer J; 2013; 19(1):34-42. PubMed ID: 23337755
[TBL] [Abstract][Full Text] [Related]
7. Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer.
Attard G; Reid AH; A'Hern R; Parker C; Oommen NB; Folkerd E; Messiou C; Molife LR; Maier G; Thompson E; Olmos D; Sinha R; Lee G; Dowsett M; Kaye SB; Dearnaley D; Kheoh T; Molina A; de Bono JS
J Clin Oncol; 2009 Aug; 27(23):3742-8. PubMed ID: 19470933
[TBL] [Abstract][Full Text] [Related]
8. The evolving paradigm of second-line hormonal therapy options for castration-resistant prostate cancer.
Courtney KD; Taplin ME
Curr Opin Oncol; 2012 May; 24(3):272-7. PubMed ID: 22327837
[TBL] [Abstract][Full Text] [Related]
9. Changing paradigms in management of metastatic Castration Resistant Prostate Cancer (mCRPC).
Gupta E; Guthrie T; Tan W
BMC Urol; 2014 Jul; 14():55. PubMed ID: 25062956
[TBL] [Abstract][Full Text] [Related]
10. [Prostate cancer and new hormonal treatments: mechanism of action and main clinical results].
Neuzillet Y; Flamand V; Lebdai S; Villers A; Lebret T
Prog Urol; 2013 Oct; 23 Suppl 1():S34-43. PubMed ID: 24314737
[TBL] [Abstract][Full Text] [Related]
11. The European medicines agency review of abiraterone for the treatment of metastatic castration-resistant prostate cancer in adult men after docetaxel chemotherapy and in chemotherapy-naive disease: summary of the scientific assessment of the committee for medicinal products for human use.
Gravanis I; Lopez AS; Hemmings RJ; Jiménez JC; Garcia-Carbonero R; Gallego IG; Giménez EV; O'Connor D; Giuliani R; Salmonson T; Pignatti F
Oncologist; 2013; 18(9):1032-42. PubMed ID: 23966222
[TBL] [Abstract][Full Text] [Related]
12. Targeting of CYP17A1 Lyase by VT-464 Inhibits Adrenal and Intratumoral Androgen Biosynthesis and Tumor Growth of Castration Resistant Prostate Cancer.
Maity SN; Titus MA; Gyftaki R; Wu G; Lu JF; Ramachandran S; Li-Ning-Tapia EM; Logothetis CJ; Araujo JC; Efstathiou E
Sci Rep; 2016 Oct; 6():35354. PubMed ID: 27748439
[TBL] [Abstract][Full Text] [Related]
13. Abiraterone in prostate cancer: a new angle to an old problem.
Stein MN; Goodin S; Dipaola RS
Clin Cancer Res; 2012 Apr; 18(7):1848-54. PubMed ID: 22451619
[TBL] [Abstract][Full Text] [Related]
14. [Abiraterone acetate(ZYTIGA®)-development and literature review].
Nishimura Y; Mukai H; Suzukawa K; Oyama R
Gan To Kagaku Ryoho; 2014 Jul; 41(7):811-6. PubMed ID: 25131865
[TBL] [Abstract][Full Text] [Related]
15. The role of abiraterone acetate in the management of prostate cancer: a critical analysis of the literature.
Sonpavde G; Attard G; Bellmunt J; Mason MD; Malavaud B; Tombal B; Sternberg CN
Eur Urol; 2011 Aug; 60(2):270-8. PubMed ID: 21550166
[TBL] [Abstract][Full Text] [Related]
16. A bypass mechanism of abiraterone-resistant prostate cancer: Accumulating CYP17A1 substrates activate androgen receptor signaling.
Moll JM; Kumagai J; van Royen ME; Teubel WJ; van Soest RJ; French PJ; Homma Y; Jenster G; de Wit R; van Weerden WM
Prostate; 2019 Jun; 79(9):937-948. PubMed ID: 31017696
[TBL] [Abstract][Full Text] [Related]
17. Improved therapeutic targeting of the androgen receptor: rational drug design improves survival in castration-resistant prostate cancer.
Lim AC; Attard G
Curr Drug Targets; 2013 Apr; 14(4):408-19. PubMed ID: 23565754
[TBL] [Abstract][Full Text] [Related]
18. Abiraterone acetate, a novel adrenal inhibitor in metastatic castration-resistant prostate cancer.
Salem M; Garcia JA
Curr Oncol Rep; 2011 Apr; 13(2):92-6. PubMed ID: 21243537
[TBL] [Abstract][Full Text] [Related]
19. [Castration resistant prostate cancer 2011].
Miller K
Aktuelle Urol; 2011 Mar; 42(2):95-102. PubMed ID: 21437832
[TBL] [Abstract][Full Text] [Related]
20. Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who received prior ketoconazole therapy.
Ryan CJ; Smith MR; Fong L; Rosenberg JE; Kantoff P; Raynaud F; Martins V; Lee G; Kheoh T; Kim J; Molina A; Small EJ
J Clin Oncol; 2010 Mar; 28(9):1481-8. PubMed ID: 20159824
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
